exel
EXEL36.950USD
-0.029-0.08%
종가 05/13, 16:00（ET）시세는 15분 지연됩니다
10.41B시가총액
19.97P/E TTM
자세한 내용은 Exelixis Inc 회사
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
회사 정보
회사 코드EXEL
회사 이름Exelixis Inc
상장일Apr 11, 2000
설립일1994
CEODr. Michael M. Morrissey, Ph.D.
직원 수1147
유형Ordinary Share
회계 연도 종료Apr 11
주소1851 Harbor Bay Parkway
도시ALAMEDA
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호94502
전화16508377000
웹사이트https://www.exelixis.com/
회사 코드EXEL
상장일Apr 11, 2000
설립일1994
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.37M
+33.08%
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
1.26M
+0.15%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
469.73K
+48.81%
Dr. Dana T. Aftab, Ph.D.
Dr. Dana T. Aftab, Ph.D.
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
390.01K
-0.39%
Mr. Patrick Joseph Haley
Mr. Patrick Joseph Haley
Executive Vice President - Commercial
Executive Vice President - Commercial
347.62K
+75.36%
Mr. Jack L. Wyszomierski
Mr. Jack L. Wyszomierski
Independent Director
Independent Director
337.77K
+2.73%
Dr. Amy C. Peterson, M.D.
Dr. Amy C. Peterson, M.D.
Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
192.16K
+486.28%
Dr. George H. Poste, Ph.D.
Dr. George H. Poste, Ph.D.
Independent Director
Independent Director
150.18K
+1.27%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
72.17K
+2.67%
Ms. Julie Anne Smith
Ms. Julie Anne Smith
Independent Director
Independent Director
763.00
-92.92%
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.37M
+33.08%
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
1.26M
+0.15%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
469.73K
+48.81%
Dr. Dana T. Aftab, Ph.D.
Dr. Dana T. Aftab, Ph.D.
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
390.01K
-0.39%
Mr. Patrick Joseph Haley
Mr. Patrick Joseph Haley
Executive Vice President - Commercial
Executive Vice President - Commercial
347.62K
+75.36%
Mr. Jack L. Wyszomierski
Mr. Jack L. Wyszomierski
Independent Director
Independent Director
337.77K
+2.73%
수익 분석
통화: USD업데이트 시간: Sun, Apr 6
통화: USD업데이트 시간: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
사업별USD
이름
수익
비율
CABOMETYX
1.80B
82.92%
License revenues
349.24M
16.10%
COMETRIQ
11.16M
0.51%
Collaboration services revenues
10.06M
0.46%
지역별USD
이름
수익
비율
U.S
1.82B
84.06%
Europe
318.63M
14.69%
Japan
27.08M
1.25%
사업별
지역별
사업별USD
이름
수익
비율
CABOMETYX
1.80B
82.92%
License revenues
349.24M
16.10%
COMETRIQ
11.16M
0.51%
Collaboration services revenues
10.06M
0.46%
주주
업데이트 시간: Tue, May 13
업데이트 시간: Tue, May 13
주주 통계
유형
주주 통계
주주
비율
The Vanguard Group, Inc.
10.38%
BlackRock Institutional Trust Company, N.A.
9.61%
Farallon Capital Management, L.L.C.
8.51%
Renaissance Technologies LLC
5.55%
State Street Global Advisors (US)
4.14%
Other
61.81%
주주 통계
주주
비율
The Vanguard Group, Inc.
10.38%
BlackRock Institutional Trust Company, N.A.
9.61%
Farallon Capital Management, L.L.C.
8.51%
Renaissance Technologies LLC
5.55%
State Street Global Advisors (US)
4.14%
Other
61.81%
유형
주주
비율
Investment Advisor/Hedge Fund
35.45%
Investment Advisor
33.07%
Hedge Fund
18.82%
Pension Fund
3.00%
Individual Investor
2.28%
Research Firm
1.80%
Sovereign Wealth Fund
1.22%
Bank and Trust
0.49%
Family Office
0.10%
Other
3.77%
기관 주식 보유
업데이트 시간: Mon, Jan 20
업데이트 시간: Mon, Jan 20
보고 기간
기관 수
보유 주식
비율
변동
2025Q1
1015
267.77M
97.13%
-1.23M
2024Q4
992
262.76M
93.66%
-11.36M
2024Q3
924
259.58M
90.96%
-10.18M
2024Q2
908
255.61M
87.75%
-22.29M
2024Q1
905
264.69M
87.26%
-20.82M
2023Q4
882
270.85M
87.07%
-16.64M
2023Q3
847
278.02M
87.32%
-18.15M
2023Q2
833
285.95M
87.85%
-21.34M
2023Q1
841
294.75M
90.97%
-14.08M
2022Q4
839
295.50M
91.62%
-5.46M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
The Vanguard Group, Inc.
29.37M
10.49%
+120.47K
+0.41%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
26.71M
9.54%
-308.83K
-1.14%
Dec 31, 2024
Farallon Capital Management, L.L.C.
23.44M
8.37%
--
--
Mar 05, 2025
Renaissance Technologies LLC
15.30M
5.47%
-64.05K
-0.42%
Dec 31, 2024
State Street Global Advisors (US)
11.41M
4.08%
-31.73K
-0.28%
Dec 31, 2024
LSV Asset Management
8.17M
2.92%
+67.47K
+0.83%
Dec 31, 2024
Fuller & Thaler Asset Management Inc.
7.63M
2.73%
+708.31K
+10.23%
Dec 31, 2024
Geode Capital Management, L.L.C.
5.16M
1.84%
-5.12K
-0.10%
Dec 31, 2024
Invesco Capital Management LLC
3.19M
1.14%
+2.62M
+466.86%
Dec 31, 2024
Dimensional Fund Advisors, L.P.
5.10M
1.82%
-153.57K
-2.92%
Dec 31, 2024
더 보기
관련 ETF
업데이트 시간: Tue, May 6
업데이트 시간: Tue, May 6
이름
비율
iShares Genomics Immunology and Healthcare ETF
4.55%
Tema Oncology ETF
4.04%
Burney US Factor Rotation ETF
3.38%
First Trust NYSE Arca Biotechnology Index Fund
3.17%
Rayliant Quantitative Developed Market Equity ETF
2.99%
Alger Russell Innovation ETF
2.96%
ERShares Entrepreneurs ETF
2.66%
Invesco Biotechnology & Genome ETF
2.58%
Range Cancer Immunotherapy ETF
2.37%
First Trust Health Care Alphadex Fund
2.34%
더 보기
iShares Genomics Immunology and Healthcare ETF
비율4.55%
Tema Oncology ETF
비율4.04%
Burney US Factor Rotation ETF
비율3.38%
First Trust NYSE Arca Biotechnology Index Fund
비율3.17%
Rayliant Quantitative Developed Market Equity ETF
비율2.99%
Alger Russell Innovation ETF
비율2.96%
ERShares Entrepreneurs ETF
비율2.66%
Invesco Biotechnology & Genome ETF
비율2.58%
Range Cancer Immunotherapy ETF
비율2.37%
First Trust Health Care Alphadex Fund
비율2.34%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음